Skip to main content

Table 4 Cost-effectiveness of bisphosphonates for real-world and ideal persistence alternatives

From: Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France

Alternatives   No-treatment Real-world persistence Ideal persistence
Costs (Discounted) Average per patients €3,402 €3,110 €2,833
  Incremental -- -€293* -€277**
Costs (Undiscounted) Average per patients 4,428 € €3,979 €3,529
  Incremental -- -€449* -€450**
Fractured women Proportion 0.671 0.600 0.491
  Incremental -- -0.071 -0.109††
ICER Discounted -- (Dominated)
€4,110
(Dominated)
€2,535
  Undiscounted -- (Dominated)
€6,310
(Dominated)
€4,114
Premature deaths Proportion 0.061 0.049 0.034
  Incremental -- -0,012 -0,015††
ICER Discounted -- (Dominated)
€25,073
(Dominated)
€18,442
  Undiscounted -- (Dominated)
€38,489
(Dominated)
€29,932
  1. * μc Real-world persistence--μc No treatment; ** μc Ideal persistence--μc Real-world persistence
  2. μE Real-world persistence--μE No treatment; †† μE Ideal persistence--μE Real-world persistence
\